{"result": {"id": "1c8e90dc-b415-48da-8da3-9d328ede938c", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>CYP3A4/5<|>ORGANIZATION<|>CYP3A4/5 is a metabolic enzyme involved in drug metabolism, with strong and moderate inhibitors listed)\n##\n(\"entity\"<|>CYP2C9<|>ORGANIZATION<|>CYP2C9 is a metabolic enzyme involved in drug metabolism, with inhibitors listed)\n##\n(\"entity\"<|>CYP2C19<|>ORGANIZATION<|>CYP2C19 is a metabolic enzyme involved in drug metabolism, with inhibitors listed)\n##\n(\"entity\"<|>CYP2C8<|>ORGANIZATION<|>CYP2C8 is a metabolic enzyme involved in drug metabolism, with inhibitors and inducers listed)\n##\n(\"entity\"<|>CYP2D6<|>ORGANIZATION<|>CYP2D6 is a metabolic enzyme involved in drug metabolism, with inhibitors listed)\n##\n(\"entity\"<|>P-GP<|>ORGANIZATION<|>P-gp is a transporter protein involved in drug metabolism, with inhibitors listed)\n##\n(\"entity\"<|>二甲双胍<|>ORGANIZATION<|>二甲双胍 is an oral hypoglycemic agent with specific pharmacokinetic parameters)\n##\n(\"entity\"<|>格列本脲<|>ORGANIZATION<|>格列本脲 is an oral hypoglycemic agent metabolized by CYP2C9)\n##\n(\"entity\"<|>格列美脲<|>ORGANIZATION<|>格列美脲 is an oral hypoglycemic agent metabolized by CYP2C9)\n##\n(\"entity\"<|>格列齐特缓释片<|>ORGANIZATION<|>格列齐特缓释片 is an oral hypoglycemic agent metabolized by CYP2C9 and CYP2C19)\n##\n(\"entity\"<|>格列吡嗪<|>ORGANIZATION<|>格列吡嗪 is an oral hypoglycemic agent metabolized by CYP2C9)\n##\n(\"entity\"<|>格列喹酮<|>ORGANIZATION<|>格列喹酮 is an oral hypoglycemic agent with specific pharmacokinetic parameters)\n##\n(\"entity\"<|>那格列奈<|>ORGANIZATION<|>那格列奈 is an oral hypoglycemic agent metabolized by CYP2C9 and CYP3A4)\n##\n(\"entity\"<|>瑞格列奈<|>ORGANIZATION<|>瑞格列奈 is an oral hypoglycemic agent metabolized by CYP2C8 and CYP3A4)\n##\n(\"entity\"<|>阿卡波糖<|>ORGANIZATION<|>阿卡波糖 is an oral hypoglycemic agent with specific pharmacokinetic parameters)\n##\n(\"entity\"<|>伏格列波糖<|>ORGANIZATION<|>伏格列波糖 is an oral hypoglycemic agent with specific pharmacokinetic parameters)\n##\n(\"entity\"<|>米格列醇<|>ORGANIZATION<|>米格列醇 is an oral hypoglycemic agent with specific pharmacokinetic parameters)\n##\n(\"entity\"<|>罗格列酮<|>ORGANIZATION<|>罗格列酮 is an oral hypoglycemic agent metabolized by CYP2C8 and CYP2C9)\n##\n(\"entity\"<|>吡格列酮<|>ORGANIZATION<|>吡格列酮 is an oral hypoglycemic agent metabolized by CYP2C8 and CYP3A4)\n##\n(\"entity\"<|>西格列汀<|>ORGANIZATION<|>西格列汀 is an oral hypoglycemic agent with minimal metabolism by CYP3A4 and CYP2C8)\n##\n(\"entity\"<|>维格列汀<|>ORGANIZATION<|>维格列汀 is an oral hypoglycemic agent with minimal metabolism by CYP450)\n##\n(\"entity\"<|>沙格列汀<|>ORGANIZATION<|>沙格列汀 is an oral hypoglycemic agent metabolized by CYP3A4/5)\n##\n(\"entity\"<|>阿格列汀<|>ORGANIZATION<|>阿格列汀 is an oral hypoglycemic agent with minimal metabolism)\n##\n(\"entity\"<|>利格列汀<|>ORGANIZATION<|>利格列汀 is an oral hypoglycemic agent with minimal metabolism)\n##\n(\"entity\"<|>达格列净<|>ORGANIZATION<|>达格列净 is an oral hypoglycemic agent metabolized by UGT1A9)\n##\n(\"entity\"<|>卡格列净<|>ORGANIZATION<|>卡格列净 is an oral hypoglycemic agent with minimal metabolism by CYP3A4)\n##\n(\"entity\"<|>李光伟<|>PERSON<|>李光伟 is a person mentioned in the text)\n##\n(\"entity\"<|>李强<|>PERSON<|>李强 is a person mentioned in the text)\n##\n(\"entity\"<|>刘幼硕<|>PERSON<|>刘幼硕 is a person mentioned in the text)\n##\n(\"relationship\"<|>格列本脲<|>CYP2C9<|>格列本脲 is metabolized by CYP2C9<|>8)\n##\n(\"relationship\"<|>格列美脲<|>CYP2C9<|>格列美脲 is metabolized by CYP2C9<|>8)\n##\n(\"relationship\"<|>格列齐特缓释片<|>CYP2C9<|>格列齐特缓释片 is metabolized by CYP2C9<|>8)\n##\n(\"relationship\"<|>格列齐特缓释片<|>CYP2C19<|>格列齐特缓释片 is metabolized by CYP2C19<|>8)\n##\n(\"relationship\"<|>格列吡嗪<|>CYP2C9<|>格列吡嗪 is metabolized by CYP2C9<|>8)\n##\n(\"relationship\"<|>那格列奈<|>CYP2C9<|>那格列奈 is metabolized by CYP2C9<|>8)\n##\n(\"relationship\"<|>那格列奈<|>CYP3A4<|>那格列奈 is metabolized by CYP3A4<|>8)\n##\n(\"relationship\"<|>瑞格列奈<|>CYP2C8<|>瑞格列奈 is metabolized by CYP2C8<|>8)\n##\n(\"relationship\"<|>瑞格列奈<|>CYP3A4<|>瑞格列奈 is metabolized by CYP3A4<|>8)\n##\n(\"relationship\"<|>罗格列酮<|>CYP2C8<|>罗格列酮 is metabolized by CYP2C8<|>8)\n##\n(\"relationship\"<|>罗格列酮<|>CYP2C9<|>罗格列酮 is metabolized by CYP2C9<|>8)\n##\n(\"relationship\"<|>吡格列酮<|>CYP2C8<|>吡格列酮 is metabolized by CYP2C8<|>8)\n##\n(\"relationship\"<|>吡格列酮<|>CYP3A4<|>吡格列酮 is metabolized by CYP3A4<|>8)\n##\n(\"relationship\"<|>西格列汀<|>CYP3A4<|>西格列汀 is minimally metabolized by CYP3A4<|>5)\n##\n(\"relationship\"<|>西格列汀<|>CYP2C8<|>西格列汀 is minimally metabolized by CYP2C8<|>5)\n##\n(\"relationship\"<|>沙格列汀<|>CYP3A4/5<|>沙格列汀 is metabolized by CYP3A4/5<|>8)\n##\n(\"relationship\"<|>卡格列净<|>CYP3A4<|>卡格列净 is minimally metabolized by CYP3A4<|>5)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752166558, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 1807, "prompt_tokens": 2704, "total_tokens": 4511, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 1792}, "prompt_cache_hit_tokens": 1792, "prompt_cache_miss_tokens": 912}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: �物名称\nCYP3A4/5 强抑制剂\t伊曲康唑、伏立康唑、克拉霉素、替利霉素、阿扎那韦、茚地那韦、奈非那韦、利托那韦、沙奎那韦、胺碘酮\nCYP3A4/5 中抑制剂\t地尔硫卓、红霉素、氟康唑、维拉帕米、葡萄柚汁\nCYP2C9 抑制剂\t氟康唑、胺碘酮\nCYP2C19 抑制剂\t奥美拉唑、氟伏沙明、氟西汀\nCYP2C8 抑制剂\t吉非罗齐、氯吡格雷\nCYP2D6 抑制剂\t胺碘酮、帕罗西汀、西咪替汀、氟西汀\nCYP3A4 强诱导剂\t利福平、卡马西平、苯巴比妥、苯妥英、地塞米松\nCYP2C8 诱导剂\t利福平\nCYP2C9 诱导剂\t卡马西平、利福平、巴比妥类\nCYP2C19 诱导剂\t利福平、苯妥英\nP-gp 抑制剂\t维拉帕米、环孢素、克拉霉素\n表 14    常用口服降糖药的药动学参数比较\nTable 14     Comparison of pharmacokinetic parameters of commonly used oral hypoglycemic agents\n\n药物名称\tt1/2（h）\t血浆蛋白结合率（%）\t代谢酶\t经粪便排出（%）\t经尿液排出\n二甲双胍\t1.7~4.5\t0\t-\t-\t24 h 排泄 90%\n格列本脲\t5\t95\tCYP2C9\t50\t50%\n格列美脲\t5~8\t99\tCYP2C9\t35\t58%\n格列齐特缓释片\t12~20\t95\tCYP2C9、CYP2C19\t-\t大部分\n格列吡嗪\t-\t99\tCYP2C9\t10~20\t60%~70%\n格列喹酮\t1~2\t-\t-\t-\t5%\n那格列奈\t1.5\t98\tCYP2C9、CYP3A4\t-\t85%\n瑞格列奈\t1\t98\tCYP2C8、CYP3A4\t90\t8%\n阿卡波糖\t3.7\t-\t-\t50\t35%\n伏格列波糖\t-\t-\t-\t几乎全部\t-\n米格列醇\t2\t4\t-\t-\t95% 原型\n罗格列酮\t3~4\t99.8\tCYP2C8、CYP2C9\t23\t64%\n吡格列酮\t3~7\t99\tCYP2C8、CYP3A4\t>85\t-\n西格列汀\t1~4\t38\t少量（CYP3A4 和 CYP2C8）\t13\t87%（80% 原型）\n维格列汀\t1~2\t9.3\t少 量（约 55% 经 非 CYP450 途径水解代谢，LAY151）\t15\t85%（21%~33% 原型）\n沙格列汀\tSax：2,\n活性产物：4\t<10\tCYP3A4/5 与 强 效 CYP3A4/5 抑制剂合用时 2.5 mg/d\t22\t75%（24% 原型，36% 活性产物）\n阿格列汀\t1~2\t20\t很少代谢\t-\t60%~76% 原型\n利格列汀\t1~3\t70\t很少代谢\t95\t<5%\n达格列净\t12.9\t91\tUGT1A9\t21\t75%\n卡格列净\t10.6~13.1\t99\t7% 经 CYP3A4\t3.2\t33% 活性产物，<1% 原型\n注：- 为无此项\n\n\n李光伟\n\n　李  强 刘幼硕 �\n######################\nOutput:", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_f3e4a17cb000ca4e6746285fb3f1df250d0d01d73ff6cd2f79d0c63a19bc06d4_v2"}